Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pamela A Moise

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
Antimicrobial Agents and Chemotherapy|November 13, 2008
Vancomycin ototoxicity: a reevaluation in an era of increasing dosesAvisheh Forouzesh, Pamela A Moise, George Sakoulas
Clinical Therapeutics|October 22, 2011
Retrospective observational study comparing vancomycin versus daptomycin as initial therapy for Staphylococcus aureus infectionsSynanda Jobson, Pamela A Moise, Romic Eskandarian
Antimicrobial Agents and Chemotherapy|April 25, 2007
Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremiaPamela A Moise, George Sakoulas, Alan Forrest, et al.
The Lancet. Infectious Diseases|September 26, 2009
Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptionsPamela A Moise, Donald North, Judith N Steenbergen, et al.
The Journal of Antimicrobial Chemotherapy|December 4, 2002
The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycinPamela A Moise, Alan Forrest, Mary C Birmingham, et al.
The Annals of Pharmacotherapy|July 9, 2009
Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapyPamela A Moise, Ellie Hershberger, Maria I Amodio-Groton, et al.
Clinical Pharmacokinetics|October 29, 2004
Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infectionsPamela A Moise-Broder, Alan Forrest, Mary C Birmingham, et al.
Annals of Plastic Surgery|April 16, 2004
Clinical experience with linezolid in conjunction with wound coverage techniques for skin and soft-tissue infections and postoperative osteomyelitisKevin W Broder, Pamela A Moise, Raymond O Schultz, et al.
Plastic and Reconstructive Surgery|May 6, 2008
Clinical experience with the Fraxel SR laser: 202 treatments in 59 consecutive patientsSteven R Cohen, Cory Henssler, Kelly Horton, et al.
The Journal of Infectious Diseases|August 21, 2012
Reduced susceptibility to host-defense cationic peptides and daptomycin coemerge in methicillin-resistant Staphylococcus aureus from daptomycin-naive bacteremic patientsNagendra N Mishra, Arnold S Bayer, Pamela A Moise, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Antimicrobial Agents and Chemotherapy|November 13, 2008
Vancomycin ototoxicity: a reevaluation in an era of increasing dosesAvisheh Forouzesh, Pamela A Moise, George Sakoulas
Clinical Therapeutics|October 22, 2011
Retrospective observational study comparing vancomycin versus daptomycin as initial therapy for Staphylococcus aureus infectionsSynanda Jobson, Pamela A Moise, Romic Eskandarian
Antimicrobial Agents and Chemotherapy|April 25, 2007
Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremiaPamela A Moise, George Sakoulas, Alan Forrest, et al.
The Lancet. Infectious Diseases|September 26, 2009
Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptionsPamela A Moise, Donald North, Judith N Steenbergen, et al.
The Journal of Antimicrobial Chemotherapy|December 4, 2002
The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycinPamela A Moise, Alan Forrest, Mary C Birmingham, et al.
The Annals of Pharmacotherapy|July 9, 2009
Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapyPamela A Moise, Ellie Hershberger, Maria I Amodio-Groton, et al.
Clinical Pharmacokinetics|October 29, 2004
Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infectionsPamela A Moise-Broder, Alan Forrest, Mary C Birmingham, et al.
Annals of Plastic Surgery|April 16, 2004
Clinical experience with linezolid in conjunction with wound coverage techniques for skin and soft-tissue infections and postoperative osteomyelitisKevin W Broder, Pamela A Moise, Raymond O Schultz, et al.
Plastic and Reconstructive Surgery|May 6, 2008
Clinical experience with the Fraxel SR laser: 202 treatments in 59 consecutive patientsSteven R Cohen, Cory Henssler, Kelly Horton, et al.
The Journal of Infectious Diseases|August 21, 2012
Reduced susceptibility to host-defense cationic peptides and daptomycin coemerge in methicillin-resistant Staphylococcus aureus from daptomycin-naive bacteremic patientsNagendra N Mishra, Arnold S Bayer, Pamela A Moise, et al.
Pageof 3